歐洲生技藥品CDMO 市場：按細胞類型、分子類型和國家：分析和預測（2023-2032 年）

歐洲生技藥品CDMO 市場規模預計將從 2023 年的 64.8 億美元增至 2032 年的 216.1 億美元，2023-2032 年預測期間複合年成長率為 14.32%。

這一市場軌跡顯示它將對醫藥保健產生變革性影響。巧妙應對複雜監管並擁抱技術創新的公司將會取得巨大成功。

在單株抗體、疫苗以及細胞和基因療法等生物療法需求不斷成長的推動下，歐洲生技藥品CDMO 市場正在經歷強勁成長。慢性病的增加、生物學的重大發展以及藥物開發和製造過程外包趨勢的上升是推動市場的主要因素。歐洲 CDMO 正在投資最先進的設施和最尖端科技，以提高產能並滿足嚴格的監管標準。策略聯盟和夥伴關係也不斷增加，使 CDMO 能夠提供從初始開發到商業生產的全面服務。憑藉政府的大力支持和成熟的生物製藥產業，歐洲生技藥品CDMO 市場有望持續擴張和創新。

該報告考察了歐洲生技藥品CDMO 市場，並提供了市場概況，包括按細胞類型、分子類型和國家分類的趨勢，以及進入市場的公司概況。

目錄

執行摘要

第1章 範圍和定義

第2章市場：產業展望

• 趨勢：當前和未來的影響評估
• 市場足跡
• 供應鏈概覽
• 專利分析
• 監管狀況
• 外包給 CDMO 時要考慮的因素
• 市場動態概覽
• 市場促進因素
• 市場限制因素
• 市場機會

第3章全球生技藥品CDMO市場，按地區，2022-2032

• 區域概況
• 促進因素和抑制因素
• 歐洲
  • 歐洲生技藥品CDMO 市場（按細胞類型）
  • 歐洲生技藥品CDMO 市場（按分子類型）
  • 歐洲（按國家/地區）

第4章市場－競爭基準化分析與公司概況

• 競爭格局
• Boehringer Ingelheim International GmbH
• Lonza
• Novartis AG

Introduction to Europe Biologics CDMO Market

The Europe biologics CDMO market is projected to reach $21.61 billion by 2032 from $6.48 billion in 2023, growing at a CAGR of 14.32% during the forecast period 2023-2032. The market's trajectory indicates a transformative impact on pharmaceutical care. Companies that skillfully navigate regulatory complexities and adopt technological innovations are well-positioned for significant success.

Market Introduction

The Europe Biologics CDMO market is experiencing robust growth, driven by increasing demand for biologic therapies, such as monoclonal antibodies, vaccines, and cell and gene therapies. The rise in chronic diseases, advancements in biology, and the growing trend of outsourcing drug development and manufacturing processes are key factors propelling the market. European CDMOs are investing in state-of-the-art facilities and cutting-edge technologies to enhance production capabilities and meet stringent regulatory standards. Strategic collaborations and partnerships are also on the rise, enabling CDMOs to offer comprehensive services from early development to commercial manufacturing. With strong government support and a well-established biopharmaceutical sector, the Europe Biologics CDMO market is poised for sustained expansion and innovation.

Market Segmentation:

Segmentation 1: by Cell Type

• Mammalian
• Microbial and Others

Segmentation 2: by Molecule Type

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Hormones
• Others

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe biologics CDMO market (by molecule type) has been segmented into different types of molecules used in developing biologics. Moreover, the study provides the reader with a detailed understanding of the different cell types and indications as well.

Growth/Marketing Strategy: The market growth and marketing strategy of biologics CDMO market revolves around a combination of technical excellence, strategic collaborations, and market positioning. CDMOs leverage their specialized expertise in bioprocessing and manufacturing to offer comprehensive solutions to biopharmaceutical companies.

Competitive Strategy: Key players in the Europe biologics CDMO market have been analyzed and profiled in the study, including CDMOs involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

• Boehringer Ingelheim Group
• Lonza Group
• NOVARTIS AG

Table of Contents

Executive Summary

1 Scope and Definition

• 1.1 Market Definition
• 1.2 Key Questions Answered in the Report
• 1.3 Analyst and Forecast Note

2 Markets: Industry Outlook

• 2.1 Trends: Current and Future Impact Assessment
  • 2.1.1 Trend 1 - Increasing Biomanufacturing Capacity
  • 2.1.2 Trend 2 - Single-use Bioprocessing Equipment
  • 2.1.3 Trend 3 - Trend Toward Personalized Medicine
• 2.2 Market Footprint
• 2.3 Supply Chain Overview
• 2.4 Patent Analysis
• 2.5 Regulatory Landscape
• 2.6 Factors Considered While Outsourcing To CDMO
• 2.7 Market Dynamics Overview
• 2.8 Market Drivers
• 2.9 Market Restraints
• 2.10 Market Opportunities

3 Global Biologics CDMO Market, by Region, 2022-2032

• 3.1 Regional Summary
• 3.2 Drivers and Restraints
• 3.3 Europe
  • 3.3.1 Europe Biologics CDMO Market, by Cell Type
  • 3.3.2 Europe Biologics CDMO Market, by Molecule Type
  • 3.3.3 Europe (by Country)
    • 3.3.3.1 Germany
      • 3.3.3.1.1 Germany Biologics CDMO Market, by Cell Type
      • 3.3.3.1.2 Germany Biologics CDMO Market, by Molecule Type
    • 3.3.3.2 U.K.
      • 3.3.3.2.1 U.K. Biologics CDMO Market, by Cell Type
      • 3.3.3.2.2 U.K. Biologics CDMO Market, by Molecule Type
    • 3.4.3.3 France
      • 3.4.3.3.1 France Biologics CDMO Market, by Cell Type
      • 3.4.3.3.2 France Biologics CDMO Market, by Molecule Type
    • 3.4.3.4 Italy
      • 3.4.3.4.1 Italy Biologics CDMO Market, by Cell Type
      • 3.4.3.4.2 Italy Biologics CDMO Market, by Molecule Type
    • 3.4.3.5 Spain
      • 3.4.3.5.1 Spain Biologics CDMO Market, by Cell Type
      • 3.4.3.5.2 Spain Biologics CDMO Market, by Molecule Type
    • 3.4.3.6 Rest-of-Europe
      • 3.4.3.6.1 Rest-of-Europe Biologics CDMO Market, by Cell Type
      • 3.4.3.6.2 Rest-of-Europe Biologics CDMO Market, by Molecule Type

4 Markets - Competitive Benchmarking & Company Profiles

• 4.1 Competitive Landscape
• 4.2 Boehringer Ingelheim International GmbH
• 4.3 Lonza
• 4.4 Novartis AG

Research Methodology